Gossamer Bio (GOSS) Prix de l'Action, Cotation, Actualités et Historique | Benzinga

Gossamer Bio Inc (GOSS) Prix de l'Action, Cotation, Actualités et Historique

GOSSNASDAQ

Trade with Public

Trade with Public

$8.43

-0.34-3.88%

Dern. MÀJ: Oct 19, 4:00 PM

$8.43

-0.34-3.88%

AperçuActualités Prévisions de résultats Événements Objectifs de cours Données financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

© 2026 Benzinga | All Rights Reserved

Statistiques Clés

Ouverture

$8.80

Clôture

$8.43

Volume / Moy.

179.47K / 373.32K

Fourchette Journalière

$8.31 - $8.89

Plage 52 Sem.

8.73 - 309.60

Capitalisation Boursière

$51.56M

Ratio P/E

-

Rendement des Dividendes

-

Échange

NASDAQ

RSI

32

Intérêt à Découvert

20.53%

Jours pour Couvrir

3.5

Actualités Récentes de Gossamer Bio, Inc.

Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones

Gossamer Bio Financing could provide up to $250 million, with much of the funding tied to seralutinib FDA milestones.

Akanksha Bakshi

This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.

Avi Kapoor

This Honeywell Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts upgraded Grupo Cibest, Lufax, Honeywell, and Gossamer Bio. JBS also received an upgrade. See what analysts think.

Avi Kapoor

Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and revenue of $4.7 billion, leading to a 4.7% jump in pre-market trading. Other top gainers include C3is, INLIF, and Polar Power. FIEE and KIDZ were among the top losers.

Avi Kapoor

Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate

Gossamer Bio plans a September 2026 NDA filing for seralutinib following FDA feedback and reacquires global rights.

Vandana Singh

Données financières

Trimestriel

Annuel

Nom

Revenu Changement
Brut Changement
EBITDA Changement
EBIT Changement
Bénéfices Changement

Flux de Trésorerie

Flux de Trésorerie Opérationnel (TTM)

-162.63M

Flux de Trésorerie d'Investissement (TTM)

174.48M

Flux de Trésorerie de Financement (TTM)

3.20M

Flux de Trésorerie Libre (TTM)

-162.63M

Dépenses en Capital (TTM)

-

Variation Nette de la Trésorerie (TTM)

15.05M

Tendances et prévisions des analystes

2

juil.

1

août

1

sept.

2

oct.

Acheter

Conserver

Vendre

Vente forte

Évaluation et prévisions des analystes

3.7

Acheter

Achat fort

Acheter

Conserver

Vendre

Vente forte

Métriques de Valorisation

Valeur Entreprise

$36.56M

Ratio P/E (TTM)

-

Ratio P/E (FWD)

-

Ratio PEG (TTM)

-

Ratio P/S (TTM)

0.53

Ratio P/B (TTM)

-

Rendement des Bénéfices % (TTM)

-603.43%

Rendement des Bénéfices % (FWD)

-66.86%

EV / EBITDA (TTM)

-

Prix / EBITDA (TTM)

-

Prix / Flux de Trésorerie Libre (TTM)

-

Valeur Comptable / Action

-$15.37

Dette Entreprise

Dette Totale

$36.15M

Dette à Long Terme

-

Émission de Dette à Long Terme (TTM)

-

Remboursement de la Dette à Long Terme (TTM)

-

Trésorerie Totale

$41.15M

Dette sur Capitaux Propres

-

Émission de Dette (TTM)

-

Remboursement de la Dette (TTM)

-